Streetbeat News

ARVN

Arvinas, Inc.

https://www.arvinas.com

Industry

Biotechnology

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Open

25.01

Mkt cap

1.5B

Volume

656K

High

25.10

P/E Ratio

-4.69

52-wk high

53.08

Low

22.46

Div yield

N/A

52-wk low

20.28

Arvinas, Inc. (ARVN) shares have seen an uptick following Goldman Sachs' initiation of coverage with a Buy rating and a $70 price target. This endorsement by a major financial institution suggests a positive outlook for Arvinas' stock in the near term.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 4:15 pm

Eaton Corporation plc (ETN) reported better-than-expected Q4 financial results, leading to a 6.2% rise in its shares. Other companies like Cimpress plc (CMPR), Nextracker Inc. (NXT), and SunPower Corporation (SPWR) also saw significant gains following positive financial results or corporate announcements. The overall market sentiment was positive, with the Dow Jones gaining over 100 points.

Portfolio Pulse from Avi Kapoor

February 01, 2024 | 3:46 pm

Analyst ratings for Arvinas (NASDAQ:ARVN) show varied sentiments, with recent updates indicating an average 12-month price target of $45.83, a significant increase from the previous $36.67. Analysts from firms like Goldman Sachs and Wells Fargo have adjusted their ratings and price targets, reflecting evolving market conditions and Arvinas's performance. Despite the optimistic analyst projections, Arvinas faces challenges such as below-average market capitalization, revenue growth below sector average, and poor profitability indicators like net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 1:00 pm

Goldman Sachs analyst Paul Choi has initiated coverage on Arvinas (NASDAQ:ARVN) with a Buy rating and set a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:04 pm

Arvinas Inc (NASDAQ:ARVN) has been analyzed by 9 analysts in the last quarter, with 4 bullish, 4 somewhat bullish, and 1 indifferent rating. The average 12-month price target is $38.44, down 15.39% from the previous $45.43. Analysts from firms like Wells Fargo, Jefferies, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Arvinas's financials show a revenue growth rate of 4.22% as of September 30, 2023, but lag behind industry peers. The company has a net margin of -184.97%, an ROE of -13.9%, an ROA of -5.98%, and a low debt-to-equity ratio of 0.01.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

Wells Fargo analyst Derek Archila has upgraded Arvinas (NASDAQ:ARVN) from Equal-Weight to Overweight and set a price target of $63.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:02 pm

Comtech Telecommunications Corp. (CMTL) shares dropped over 16% due to weaker-than-expected quarterly earnings, reporting adjusted earnings of 24 cents per share against estimates of 26 cents. Sales were nearly in line with expectations at $151.91 million versus $151.87 million forecasted. The stock fell to $10.45. Other stocks moved in the session, with notable gainers including Intensity Therapeutics (INTS), MBIA Inc. (MBI), and ALX Oncology Holdings (ALXO), among others. Losers included Cyngn Inc. (CYN), African Agriculture Holdings (AAGR), and Golden Heaven Group Holdings (GDHG).

Portfolio Pulse from Avi Kapoor

December 08, 2023 | 5:58 pm

Torrid Holdings Inc. reported better-than-expected Q3 results and raised FY23 guidance, causing its shares to jump 22.3%. MBIA Inc. declared an $8.00 per share extraordinary dividend, leading to a 63.8% share increase. Other stocks like ALX Oncology, Virco Mfg., and Bitfarms also saw significant gains after positive upgrades, earnings reports, and corporate actions.

Portfolio Pulse from Avi Kapoor

December 08, 2023 | 3:40 pm

AeroVironment, Inc. (NASDAQ:AVAV) shares fell over 9% despite reporting Q2 earnings and revenue that beat estimates. The company's adjusted earnings were 97 cents per share, surpassing the expected 62 cents, with revenue at $180.8 million against the forecasted $170.908 million. Other stocks experienced significant movements in Wednesday's mid-day session, with notable gainers including Sera Prognostics, Inc. (NASDAQ:SERA) and MicroAlgo Inc. (NASDAQ:MLGO), and losers such as NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) and ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA).

Portfolio Pulse from Lisa Levin

December 06, 2023 | 7:43 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Sera Prognostics (SERA) saw a massive increase of 231.9%, while OptiNose (OPTN) led the decliners with a 22.4% drop. Other notable gainers include Phio Pharma (PHIO), Syros Pharmaceuticals (SYRS), Altimmune (ALT), Arvinas (ARVN), and Altamira Therapeutics (CYTO). On the losing side were Mira Pharmaceuticals (MIRA), InVivo Therapeutics Hldg (NVIV), Allarity Therapeutics (ALLR), GlucoTrack (GCTK), and Sonoma Pharmaceuticals (SNOA).

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.